Kabra Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	927.4	-	-	-	-
Cost of Revenue	836.64	-	-	-	-
Gross Profit	90.76	-	-	-	-
Selling, General & Admin	14.66	7.55	4.55	2.64	1.2
Other Operating Expenses	22.81	9.63	2.82	0.81	0.55
Operating Expenses	38.18	17.25	7.36	3.44	1.84
Operating Income	52.58	-17.25	-7.36	-3.44	-1.84
Interest Expense	-0.3	-	-	-	-
Interest & Investment Income	-	-	-	0.06	-
Other Non Operating Income (Expenses)	4.93	6.4	-	-	-
EBT Excluding Unusual Items	57.21	-10.85	-7.36	-3.38	-1.84
Gain (Loss) on Sale of Investments	-	-	-	-	-0.01
Pretax Income	57.21	-10.85	-7.36	-3.38	-1.85
Income Tax Expense	7.61	0.01	-	-	-
Net Income	49.6	-10.86	-7.36	-3.38	-1.85
Net Income to Common	49.6	-10.86	-7.36	-3.38	-1.85
Shares Outstanding (Basic)	24	11	4	4	4
Shares Outstanding (Diluted)	24	11	4	4	4
Shares Change (YoY)	117.16%	149.01%	-	-	-
EPS (Basic)	2.09	-0.99	-1.68	-0.77	-0.42
EPS (Diluted)	2.09	-0.99	-1.68	-0.77	-0.42
Free Cash Flow	-101.76	-47.58	-2.09	-3.54	-1.34
Free Cash Flow Per Share	-4.29	-4.35	-0.47	-0.81	-0.30
Gross Margin	9.79%	-	-	-	-
Operating Margin	5.67%	-	-	-	-
Profit Margin	5.35%	-	-	-	-
Free Cash Flow Margin	-10.97%	-	-	-	-
EBITDA	52.95	-17.18	-	-3.34	-1.74
EBITDA Margin	5.71%	-	-	-	-
D&A For EBITDA	0.37	0.07	-	0.1	0.1
EBIT	52.58	-17.25	-7.36	-3.44	-1.84
EBIT Margin	5.67%	-	-	-	-
Effective Tax Rate	13.30%	-	-	-	-
Revenue as Reported	932.33	6.4	-	0.06	-
Advertising Expenses	-	0.17	0.19	0.09	0.07